 | |
| Clinical data | |
|---|---|
| Trade names | Renormax |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 50% |
| Metabolism | converted to spiraprilat |
| Eliminationhalf-life | 30 to 35 hours |
| Excretion | Hepatic andrenal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H30N2O5S2 |
| Molar mass | 466.61 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Spirapril, sold under the brand nameRenormax among others, is anACE inhibitorantihypertensive drug used to treathypertension. It belongs to dicarboxy group of ACE inhibitors.[citation needed]
It was patented in 1980 and approved for medical use in 1995.[1]
Like many ACE inhibitors, thisprodrug is converted to the active metabolitespiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes, which may allow for greater use in patients with renal impairment.[2]However, data on its effect upon therenal function are conflicting.[3]
Media related toSpirapril at Wikimedia Commons | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
